Lexicon Pharmaceuticals (LXRX) Cash from Financing Activities (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) reported Cash from Financing Activities of $88.8 million for Q1 2026, up 15616.78% year-over-year from N/an in Q1 2025, and up 3132.32% quarter-over-quarter from -$2.9 million in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has 17 years of Cash from Financing Activities data on file, last reported at $88.8 million in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $88.8 million, up 15616.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $40.8 million (up 2642.28% YoY), and the FY2025 annual result was -$48.5 million, down 120.35% from the prior year.
- Cash from Financing Activities grew to $88.8 million in Q1 2026 per LXRX's latest filing, from -$2.9 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $239.4 million in Q1 2024 and troughed at -$45.0 million in Q2 2025.
- A 5-year average of $40.6 million and a median of -$14000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities surged 29151.33% in 2024, then tumbled 321328.57% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $24.9 million in 2022, then plunged by 100.0% to -$1000.0 in 2023, then plunged by 10300.0% to -$104000.0 in 2024, then slumped by 2714.42% to -$2.9 million in 2025, then soared by 3132.32% to $88.8 million in 2026.
- Business Quant data shows LXRX's Cash from Financing Activities at $88.8 million in Q1 2026, -$2.9 million in Q4 2025, and -$45.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Lexicon Pharmaceuticals | 804.48 Mn | 633.82 Mn | 20.99 Mn | 88.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 88.76 Mn |
| Mar 31, 2026 | 88.76 Mn |
| Dec 31, 2025 | -2.93 Mn |
| Dec 31, 2025 | -2.93 Mn |
| Jun 30, 2025 | -45.00 Mn |
| Jun 30, 2025 | -45.00 Mn |
| Mar 31, 2025 | -572,000.00 |
| Mar 31, 2025 | -572,000.00 |
| Dec 31, 2024 | -104,000.00 |
| Dec 31, 2024 | -104,000.00 |
| Sep 30, 2024 | -916,000.00 |
| Sep 30, 2024 | -916,000.00 |
| Jun 30, 2024 | -14,000.00 |
| Jun 30, 2024 | -14,000.00 |
| Mar 31, 2024 | 239.38 Mn |
| Mar 31, 2024 | 239.38 Mn |
| Dec 31, 2023 | -1,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Sep 30, 2023 | -210,000.00 |
| Sep 30, 2023 | -210,000.00 |